R. Schiavon

Extra-Haematological Comorbidities, Transfusion Dependency and Polypharmacy in Older Adults with Low Risk Myelodisplatic Syndromes

R. Castelli, R. Schiavon, 2018 .

Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents

V. Rossi, R. Castelli, G. L. Deliliers, 2018, Medical Oncology.

High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation

P. Gallipoli, L. Bergamaschini, R. Castelli, 2017, Journal of Thrombosis and Thrombolysis.

Drug-eluting stents vs. bare metal stents in elderly patients

F. Leidi, R. Schiavon, On behalf of Gruppo di Autoformazione Metodologica, 2018, Internal and Emergency Medicine.

Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.

P. Gallipoli, L. Bergamaschini, R. Castelli, 2020, Clinical lymphoma, myeloma & leukemia.

Personalized treatment strategies for elderly patients with myelodysplastic syndromes

L. Bergamaschini, R. Castelli, R. Schiavon, 2017, Expert review of hematology.

The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes

R. Castelli, G. L. Deliliers, R. Schiavon, 2018, Medical Oncology.

HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy

L. Ferraris, R. Castelli, C. Preti, 2020, Cardiovascular & hematological disorders drug targets.